PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26465152-0 2015 A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. Steroids 68-75 calcineurin binding protein 1 Homo sapiens 116-137 31049814-1 2020 BACKGROUND: Tacrolimus, a calcineurin inhibitor, is recommended by the recent guidelines from the Kidney Disease Improving Global Outcomes Group as the first-line treatment for steroid-resistant nephrotic syndrome (SRNS), but its clinical application in China is still limited. Steroids 177-184 calcineurin binding protein 1 Homo sapiens 26-47 30983748-0 2019 Loss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naive Adult-Onset Primary Focal Segmental Glomerulosclerosis. Steroids 67-74 calcineurin binding protein 1 Homo sapiens 85-106 30983748-4 2019 Diagnostic biopsies of adult-onset steroid-resistant calcineurin inhibitor-naive primary FSGS cases, which were subsequently treated with tacrolimus were included in this retrospective study conducted from 2011 to 2013. Steroids 35-42 calcineurin binding protein 1 Homo sapiens 53-74 30298667-5 2018 Calcineurin inhibitor and cyclophosphamide are recommended in steroid-dependent/steroid-resistant patients. Steroids 62-69 calcineurin binding protein 1 Homo sapiens 0-21 30298667-5 2018 Calcineurin inhibitor and cyclophosphamide are recommended in steroid-dependent/steroid-resistant patients. Steroids 80-87 calcineurin binding protein 1 Homo sapiens 0-21 25121488-3 2015 OUTCOMES: Therapy in patients with steroid dependence and CNI-dependent steroid resistance led to significantly reduced relapse rates (respective mean difference 2.7 relapses/year and 2.2 relapses/year, corresponding to a decrease in relapses by 81.8 and 71.0%; both P < 0.0001). Steroids 72-79 calcineurin binding protein 1 Homo sapiens 58-61 25121488-5 2015 Remission was longer in patients with steroid dependence compared with CNI-dependent steroid resistance (median 16 versus 10 months; P < 0.0001). Steroids 85-92 calcineurin binding protein 1 Homo sapiens 71-74 25121488-6 2015 Prior response to cyclophosphamide predicted a lower risk of relapse in the former (hazard ratio, HR 0.56; P = 0.045); patients with initial resistance and CNI-dependent steroid resistance had increased risk of relapse (HR 2.66; P = 0.042). Steroids 170-177 calcineurin binding protein 1 Homo sapiens 156-159 25121488-11 2015 CONCLUSIONS: Therapy with rituximab is effective and safe in reducing relapse rates and need for immunosuppressive medications in patients with steroid-dependent and CNI-dependent steroid-resistant nephrotic syndrome. Steroids 180-187 calcineurin binding protein 1 Homo sapiens 166-169 23731524-3 2013 Calcineurin-inhibitor based steroid-containing regimens have been the mainstay of maintenance immunosuppression over the last two decades. Steroids 28-35 calcineurin binding protein 1 Homo sapiens 0-21 22320241-1 2012 Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study). Steroids 139-147 calcineurin binding protein 1 Homo sapiens 22-43 23291669-1 2013 OBJECTIVE: The calcineurin inhibitor tacrolimus has been shown to be safe and effective as salvage therapy for steroid-refractory ulcerative colitis (UC). Steroids 111-118 calcineurin binding protein 1 Homo sapiens 15-36 22645323-7 2012 CONCLUSIONS: A regimen of early intensified EC-MPS dosing with calcineurin inhibitor and IL-2RA induction permits oral steroid avoidance in adult kidney transplant patients at low-immunological risk without compromising efficacy at 6 months" follow-up. Steroids 119-126 calcineurin binding protein 1 Homo sapiens 63-84 17616271-4 2007 The approval of the new immunosuppressive agents: rabbit antithymocyte globulin, basiliximab, daclizumab, tacrolimus, mycophenolate, and sirolimus, also has facilitated the development of steroid- and calcineurin inhibitor-sparing regimens in kidney transplantation. Steroids 188-195 calcineurin binding protein 1 Homo sapiens 201-222 20238230-1 2010 Although most patients with idiopathic nephrotic syndrome (NS) respond to steroid treatment, development of steroid dependency may require a long-term multidrug therapy including steroid and calcineurin inhibitor. Steroids 108-115 calcineurin binding protein 1 Homo sapiens 191-212 20238230-1 2010 Although most patients with idiopathic nephrotic syndrome (NS) respond to steroid treatment, development of steroid dependency may require a long-term multidrug therapy including steroid and calcineurin inhibitor. Steroids 108-115 calcineurin binding protein 1 Homo sapiens 191-212 21436979-3 2009 Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Steroids 137-144 calcineurin binding protein 1 Homo sapiens 14-35 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Steroids 54-62 calcineurin binding protein 1 Homo sapiens 182-185 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Steroids 54-62 calcineurin binding protein 1 Homo sapiens 182-185 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Steroids 161-169 calcineurin binding protein 1 Homo sapiens 182-185 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Steroids 161-169 calcineurin binding protein 1 Homo sapiens 182-185 18209989-4 2008 To prevent steroid side effects and most importantly nephrotoxicity, the roles of antimetabolites such as mycophenolate and calcineurin inhibitor reduction have become more important. Steroids 11-18 calcineurin binding protein 1 Homo sapiens 124-145 20175769-1 2010 BACKGROUND: The calcineurin inhibitor tacrolimus and the anti-TNF-antibody infliximab are established options in steroid-refractory ulcerative colitis (UC). Steroids 113-120 calcineurin binding protein 1 Homo sapiens 16-37 18562571-3 2008 In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based CNI withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients. Steroids 145-153 calcineurin binding protein 1 Homo sapiens 106-109 17302598-16 2007 CONCLUSION: Early steroid-withdrawal in renal transplant recipients with a sirolimus and CellCept-based calcineurin inhibitor-minimimization protocol can effectively reduce many of the steroid-related side effects, decrease risk factors for cardiovascular disease, and is associated with improved recipient survival without compromising graft function. Steroids 18-25 calcineurin binding protein 1 Homo sapiens 104-125 17302598-16 2007 CONCLUSION: Early steroid-withdrawal in renal transplant recipients with a sirolimus and CellCept-based calcineurin inhibitor-minimimization protocol can effectively reduce many of the steroid-related side effects, decrease risk factors for cardiovascular disease, and is associated with improved recipient survival without compromising graft function. Steroids 185-192 calcineurin binding protein 1 Homo sapiens 104-125 32651716-1 2021 BACKGROUND: Calcineurin inhibitor (CNI) use in genetic steroid-resistant nephrotic syndrome (SRNS) is controversial as response rate is reported to be lower than non-genetic disease and no plausible mechanism of action is known. Steroids 55-62 calcineurin binding protein 1 Homo sapiens 12-33 33186226-4 2021 The AURORA trial reported positive results for the calcineurin inhibitor voclosporin as an oral add-on therapy to low dose steroids and MMF when given twice daily over a period of 52 weeks at an effect size of 18.5% for a CRR. Steroids 123-131 calcineurin binding protein 1 Homo sapiens 51-72